Cargando…

Clinical Utility of Romosozumab in the Management of Osteoporosis: Focus on Patient Selection and Perspectives

As one of the most potent osteoanabolic agents with a unique mechanism of action, romosozumab has high efficacy for osteoporosis treatment. It is a monoclonal antibody against sclerostin, a natural inhibitor of the Wnt signaling pathway, and by inhibiting sclerostin, activation of Wnt signaling occu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Sian Yik, Bolster, Marcy B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762257/ https://www.ncbi.nlm.nih.gov/pubmed/36544862 http://dx.doi.org/10.2147/IJWH.S315184

Ejemplares similares

Profile of romosozumab and its potential in the management of osteoporosis
por: Lim, Sian Yik, et al.
Publicado: (2017)

Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk
por: Lim, Sian Yik
Publicado: (2022)

Romosozumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2018)

Romosozumab for osteoporosis
Publicado: (2021)

Romosozumab in osteoporosis: yesterday, today and tomorrow
por: Wu, Dong, et al.
Publicado: (2023)

Romosozumab, clinical trials, and real-world care of patients with osteoporosis
por: Lewiecki, E. Michael
Publicado: (2020)

Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient With Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Vitiligo progression in a patient undergoing romosozumab treatment for osteoporosis
por: Trepanowski, Nicole, et al.
Publicado: (2023)

Romosozumab: a novel bone anabolic treatment option for osteoporosis?
por: Kerschan-Schindl, Katharina
Publicado: (2019)

Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta
por: Dattagupta, Antara, et al.
Publicado: (2023)

Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study
por: Tominaga, A., et al.
Publicado: (2021)

Romosozumab and cardiovascular safety in Japan
por: Takeuchi, Yasuhiro
Publicado: (2021)

RF30 | PSAT138 Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient with Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2021)

Effect of Romosozumab on Trabecular Bone Score Compared to Anti-Resorptive Agents in Postmenopausal Women with Osteoporosis
por: Jeong, Chaiho, et al.
Publicado: (2022)

Pregnancy and Lactation-Associated Osteoporosis Successfully Treated with Romosozumab: A Case Report
por: Kaneuchi, Yoichi, et al.
Publicado: (2022)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

ODP132 Efficacy of Romosozumab for Osteoporosis in a Patient with Hajdu-Cheney Syndrome: A Case Report
por: Kim, Kyoung Jin, et al.
Publicado: (2022)

Romosozumab and Blosozumab: Alternative Drugs of Mechanical Strain-Related Stimulus Toward a Cure for Osteoporosis
por: Sugiyama, Toshihiro, et al.
Publicado: (2015)

Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden
por: Söreskog, E., et al.
Publicado: (2021)

Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild‐to‐Moderate Chronic Kidney Disease
por: Miller, Paul D, et al.
Publicado: (2022)

Romosozumab in Postmenopausal Korean Women with Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study
por: Baek, Ki-Hyun, et al.
Publicado: (2021)

The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study
por: Geusens, Piet, et al.
Publicado: (2019)

Romosozumab versus Teriparatide for the Treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta‐analysis through a Grade Analysis of Evidence
por: Tian, Aixian, et al.
Publicado: (2021)

Time-Course Changes in Bone Metabolism Markers and Density in Patients with Osteoporosis Treated with Romosozumab: A Multicenter Retrospective Study
por: Inage, Kazuhide, et al.
Publicado: (2021)

Clinical Evaluation of Dapagliflozin in the Management of CKD: Focus on Patient Selection and Clinical Perspectives
por: Nashar, Khaled, et al.
Publicado: (2022)

Romosozumab and antiresorptive treatment: the importance of treatment sequence
por: Cosman, Felicia, et al.
Publicado: (2022)

Romosozumab efficacy and safety in European patients enrolled in the FRAME trial
por: Langdahl, Bente, et al.
Publicado: (2022)

Impact of romosozumab on serum calcium concentration and factors predicting the fluctuations in calcium concentration upon romosozumab administration: A multicenter retrospective study
por: Inose, Hiroyuki, et al.
Publicado: (2022)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates
por: Muratore, Maurizio, et al.
Publicado: (2011)

Treatment of postmenopausal osteoporosis, patient perspectives – focus on once yearly zoledronic acid
por: Carmona, Raj, et al.
Publicado: (2009)

MON-378 Efficacy and Safety of Romosozumab vs Alendronate Is Similar Across Different Levels of Renal Function Among Postmenopausal Women with Osteoporosis
por: Miller, Paul, et al.
Publicado: (2020)

Management of osteoporosis in the aging male: Focus on zoledronic acid
por: Piper, Paul K, et al.
Publicado: (2009)

Bone‐Forming and Antiresorptive Effects of Romosozumab in Postmenopausal Women With Osteoporosis: Bone Histomorphometry and Microcomputed Tomography Analysis After 2 and 12 Months of Treatment
por: Chavassieux, Pascale, et al.
Publicado: (2019)

OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020)

The clinical utility of bone marker measurements in osteoporosis
por: Wheater, Gillian, et al.
Publicado: (2013)

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
por: Schemitsch, Emil H., et al.
Publicado: (2020)

Balancing the risks and benefits of biologic drugs in rheumatic disease: the case for romosozumab?
por: Reid, David M.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dq58qp2156jhd6v1031btahqp5